Reuters: AstraZeneca tests diabetes drug for COVID-19

AstraZeneca Plc is testing one of its diabetes drugs as a treatment for COVID-19. 

The trial of 900 hospitalized patients, called DARE-19, will test Farxiga against a placebo with results expected by December.

Reuters talked to Dr. Mikhail Kosiborod, cardiologist at Saint Luke's Mid America Heart Institute and principal investigator of the study.

"While we don't fully understand the mechanisms of how these medications protect the heart and kidneys, we know that they do," Dr. Kosiborod said. "We know that they do that in patient populations that have cardiometabolic disease--exactly the same patient population that are at such high risk in the setting of COVID-19."

Read the full Reuters article: AstraZeneca tests diabetes drug for COVID-19

Related Content

KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
Apr. 25, 2020
KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
Blue sphere COVID-19 viruses
Apr. 25, 2020
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.